Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes : A viable strategy for COVID-19 immunosuppressed patients?
© 2021 Wiley Periodicals LLC..
Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections is on focus of research. We evaluate herein the feasibility of expanding virus-specific T cells (VST) against SARS-CoV-2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS-CoV-2 asymptomatic infection/negative serology, (b) SARS-CoV-2 symptomatic infection/positive serology, and (c) no history of SARS-CoV-2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 62.7%, respectively) with CD4 + dominance (60% in both donors). Higher numbers of VST were obtained from the donor 2 as compared to donor 1. T-cell clonality test showed oligoclonal reproducible peaks on a polyclonal background for both donors. In contrast, VST could be neither expanded nor primed in a donor without evidence of prior infection. This proof-of-concept study supports the feasibility of expanding ex vivo SARS-CoV-2-specific VST from blood of convalescent donors. The results raise the question of whether the selection of seropositive donors may be a strategy to obtain cell lines enriched in their SARS-CoV-2-specificity for future adoptive transfer to immunosuppressed patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 23(2021), 4 vom: 15. Aug., Seite e13602 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guerreiro, Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adoptive immunotherapy |
|---|
| Anmerkungen: |
Date Completed 22.09.2021 Date Revised 31.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.13602 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32285329X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32285329X | ||
| 003 | DE-627 | ||
| 005 | 20231225182925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.13602 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM32285329X | ||
| 035 | |a (NLM)33728702 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guerreiro, Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes |b A viable strategy for COVID-19 immunosuppressed patients? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2021 | ||
| 500 | |a Date Revised 31.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections is on focus of research. We evaluate herein the feasibility of expanding virus-specific T cells (VST) against SARS-CoV-2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS-CoV-2 asymptomatic infection/negative serology, (b) SARS-CoV-2 symptomatic infection/positive serology, and (c) no history of SARS-CoV-2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 62.7%, respectively) with CD4 + dominance (60% in both donors). Higher numbers of VST were obtained from the donor 2 as compared to donor 1. T-cell clonality test showed oligoclonal reproducible peaks on a polyclonal background for both donors. In contrast, VST could be neither expanded nor primed in a donor without evidence of prior infection. This proof-of-concept study supports the feasibility of expanding ex vivo SARS-CoV-2-specific VST from blood of convalescent donors. The results raise the question of whether the selection of seropositive donors may be a strategy to obtain cell lines enriched in their SARS-CoV-2-specificity for future adoptive transfer to immunosuppressed patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a adoptive immunotherapy | |
| 650 | 4 | |a lymphocyte expansion | |
| 650 | 4 | |a respiratory virus | |
| 650 | 4 | |a third-party donors | |
| 650 | 4 | |a virus-specific T cells | |
| 700 | 1 | |a Aguilar-Gallardo, Cristóbal |e verfasserin |4 aut | |
| 700 | 1 | |a Montoro, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Francés-Gómez, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Latorre, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Luna, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Planelles, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco, María Paz |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a González-Barberá, Eva María |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Sempere, Amparo |e verfasserin |4 aut | |
| 700 | 1 | |a Solves, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Seguí, Inés |e verfasserin |4 aut | |
| 700 | 1 | |a Balaguer-Rosello, Aitana |e verfasserin |4 aut | |
| 700 | 1 | |a Louro, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Perla, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Larrea, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Arbona, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a de la Rubia, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Geller, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Luis Piñana, José |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 23(2021), 4 vom: 15. Aug., Seite e13602 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:4 |g day:15 |g month:08 |g pages:e13602 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.13602 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 4 |b 15 |c 08 |h e13602 | ||